ENGLEWOOD, Colo., July 11, 2019 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage
biopharmaceutical company focused on the discovery and development
of a novel therapy aimed at treating common inflammatory conditions
for which there are limited treatment options, today announced
that its Audit Committee and Board of Directors appointed Moss
Adams LLP as the Company's new independent auditor.
Moss Adams has served for over
100 years as a fully integrated professional services firm with
over 3,200 professionals across more than 25 locations in the
western United States. Their Life
Sciences Practice provides a variety of audit, tax and consulting
services to over 550 clients of all sizes, with nearly 100 clients
in the pharmaceuticals sector.
Michael Macaluso, Ampio CEO,
noted: "As Ampio moves forward with our pivotal trial
of Ampion in adults with pain due to severe osteoarthritis of the
knee, in which we are already dosing patients, we
sought an accounting firm highly experienced in working with
clients with products at a similar stage of development. Moss
Adams perfectly fits this
requirement and is well known for their top quality, independent
audit services for companies of our size and development stage in
the life sciences market. We look forward to working with the Moss
Adams's experienced professional services team."
Moss Adams will replace
Plante Moran, PLLC who, through
their predecessor EKS&H LLP, had served as the Company's
independent auditor since 2010. The decision to change auditors was
not caused by any disagreement between the Company and Plante Moran on any matter of accounting
principles or practices, financial statement disclosure or auditing
scope or procedure.
About Osteoarthritis
Osteoarthritis (OA) is an
incurable and progressive disorder of the joints involving
degradation of the intra-articular cartilage, joint lining,
ligaments, and bone. Certain risk factors in conjunction with
natural wear and tear lead to the breakdown of cartilage. OA is
caused by inflammation of the soft tissue and bony structures of
the joint, which worsens over time and leads to progressive
thinning of articular cartilage. Other symptoms include narrowing
of the joint space, synovial membrane thickening, osteophyte
formation and increased density of subchondral bone.
About Moss Adams
LLP
Moss Adams is a fully integrated
professional services firm dedicated to assisting clients with
growing, managing, and protecting prosperity. With over 3,200
professionals and staff across more than 25 locations in the West
and beyond, Moss Adams works with many of the world's most
innovative companies and leaders. Their strength in the middle
market enables them to advise clients at all intervals of
development—from start-up, to rapid growth and expansion, to
transition.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals,
Inc. is a development stage biopharmaceutical company primarily
focused on the development of Ampion, our product candidate, to
treat prevalent inflammatory conditions for which there are limited
treatment options.
Forward-Looking Statements
Ampio's
statements in this press release that are not historical fact, and
that relate to future plans or events, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements can be identified by
the use of words such as "believe," "expect," "plan," "anticipate,"
and similar expressions. These forward-looking statements include
statements regarding Ampio's expectations with respect
to Ampion™ and its classification, as well as those associated
with regulatory approvals and other FDA decisions, the Biological
License Application (BLA) , the ability of Ampio to enter into
partnering arrangements, clinical trials and decisions and
changes in business conditions and similar events, all of which are
inherently subject to various risks and uncertainties. The risks
and uncertainties involved include those detailed from time to time
in Ampio's filings with the Securities and Exchange Commission,
including without limitation, under Ampio's Annual Report on Form
10-K and other documents filed with the Securities and Exchange
Commission. Ampio undertakes no obligation to revise or update
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Company Contact
Phone: (720) 437-6500
info@ampiopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ampio-appoints-moss-adams-llp-as-the-companys-new-independent-auditor-300883232.html
SOURCE Ampio Pharmaceuticals, Inc.